医学
表阿霉素
内科学
环磷酰胺
乳腺癌
多西紫杉醇
化疗
肿瘤科
养生
人口
骨矿物
癌症
骨质疏松症
环境卫生
作者
Bai-qing Peng,Juan Wu,Shen Tian,Xiu-quan Qu,Xinyu Liang,Jun-han Feng,Yuling Chen,Rui-ling She,Chen-yu Ma,Jing-yu Song,Zhaoxing Li,Zhi-yu Jiang,Kainan Wu,Lingquan Kong
标识
DOI:10.1007/s00520-023-07960-8
摘要
Abstract Purpose Although the therapy-related bone loss attracts increasing attention nowadays, the differences in chemotherapy-induced bone loss and bone metabolism indexes change among BC women with different menstrual statuses or chemotherapy regimens are unknown. The aim of the study is to explore the effects of different regimens of chemotherapy on bone health. Method The self-control study enrolled 118 BC patients who underwent dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) screening and (or) bone metabolism indexes monitoring during chemotherapy at Chongqing Breast Cancer Center. Mann-Whitney U test, Cochran's Q test and Wilcoxon sign rank test were performed. Results After chemotherapy, the BMD in the lumbar 1-4 and whole lumbar statistically decreased (-1.8% /per six month), leading to a significantly increased proportion of osteoporosis (27.1% vs. 20.5%, P < 0.05), which were mainly seen in the premenopausal group (-7.0% /per six month). Of the chemotherapeutic regimens of EC (epirubicin+cyclophosphamide), TC(docetaxel+cyclophosphamide), TEC (docetaxel+epirubicin+cyclophosphamide), EC-T(H) [epirubicin+cyclophosphamide-docetaxel and/or trastuzumab], EC regimen had the least adverse impact on BMD, while the EC-TH regimen reduced BMD most(P < 0.05) in spite of the none-statistical difference between EC-T regimen, which was mainly seen in the postmenopausal group. Except the postmenopausal population with calcium/VitD supplement, the albumin-adjusted calcium increased significantly(2.21mmol/L vs. 2.33 mmol/L, P < 0.05) after chemotherapy. In postmenopausal group with calcium/VitD supplement,β-CTX decreased significantly(0.56ng/ml vs. 0.39ng/ml, P < 0.05) and BMD weren’t affected by chemotherapy (P > 0. 05). In premenopausal group with calcium/VitD supplement, PTH decreased significantly (52.90pg/ml vs. 28.80pg/ml, P=0. 008) and hip BMD increased after chemotherapy (0.845g/m2 vs. 0.952g/m2, P=0. 006). As for both postmenopausal and premenopausal group without calcium/VitD supplement, there was a significant decrease in bone mass in hip and lumbar vertebrae after chemotherapy (0.831g/m2 vs. 0.776g/m2; 0.895g/m2 vs. 0.870g/m2, P < 0.05). Conclusion Chemotherapy might induce lumbar vertebrae BMD loss and spine osteoporosis with regimen differences among Chinese BC patients. Calcium/VitD supplementation could improve bone turnover markers, bone metabolism indicators and bone mineral density. Early interventions on bone health are needed for BC patients during chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI